Medicinal Products


Generic drug of Xatral LP
Therapeutic class: Urology nephrology
active ingredients: Alfuzosin
laboratory: Teva Sante

Sustained release tablet
Box of 30
All forms


Treatment of moderate to severe functional symptoms of benign prostatic hypertrophy (BPH).

Dosage ALFUZOSINE LP TEVA 10 mg prolonged release tablet Box of 30

Oral way.

The prolonged release tablet should be swallowed whole with a glass of water, without being crushed, chewed or divided (see Warnings and Precautions ).

The first dose should be taken at bedtime. Alfuzosin 10 mg prolonged-release tablets should be taken daily, immediately after the same meal.


The recommended dose is one 10 mg tablet daily.

Elderly (over 65 years old)

See "Adults". Data on pharmacokinetics and safety of use show that generally, there is no need to reduce the dose in the elderly.

Renal failure

Mild to moderate renal impairment (creatinine clearance> 30 ml / min)

Dosage adjustment is not usually necessary (see section 5.2 ).

Severe renal insufficiency (creatinine clearance <30 ml / min)

Due to the lack of safety data, alfuzosin 10 mg prolonged-release tablets should not be prescribed in patients with severe renal impairment (see Warnings and Precautions section). employment ).

Hepatic insufficiency

Alfuzosin 10 mg prolonged release tablets are contraindicated in patients with hepatic impairment. In the opinion of the physician, a preparation containing a lower dose of alfuzosin hydrochloride may be considered appropriate. For dosing recommendations the SPC of the corresponding specialty should be consulted.

ALFUZOSINE TEVA LP 10 mg is not indicated in children.

Against indications

· Persistence with alfuzosin, other quinazolines (eg terazosin, doxazosin) or with any of the excipients.

· Orthostatic hypotension.

· Severe hepatic insufficiency.

· A combination with other alpha-1 blockers.

Adverse effects Alfuzosine LP Teva

The undesirable effects considered to be possibly related to the treatment are listed below by organ system classes and by absolute frequency. The defined frequencies are: very frequent (≥1 / 10); frequent (≥ 1/100 to <1/10); uncommon (≥ 1/1000 to <1/100); rare (≥ 1/10 000 to <1/1000); very rare (<1 / 10, 000); indeterminate frequency (can not be estimated based on available data).




Very rare


Blood and lymphatic system disorders


Nervous system disorders

Dizziness / tiredness, vertigo, headache

Drowsiness, syncope

Eye disorders

Visual disorders

Intraoperative flaccid iris syndrome

Heart conditions

Tachycardia, palpitations

Aggravation or recurrence of angina in patients with pre-existing coronary artery disease (see Warnings and Precautions section )

Atrial fibrillation

Vascular disorders

Orthostatic hypotension (at the beginning of treatment, mainly because of a dose that is too high, or if treatment is resumed after a short interruption)


Respiratory, thoracic and mediastinal disorders


Gastrointestinal disorders

Nausea, abdominal pain, diarrhea, dry mouth


Hepatobiliary disorders

Hepatocellular lesion, cholestatic liver disease

Skin and subcutaneous tissue disorders

Rashes, pruritus

Urinary angioneurotic edema

Disorders of reproductive organs and breast


General disorders and administration site conditions

Asthenia, discomfort

Edema, chest pain (see section Warnings and precautions for use )

Popular Posts

Category Medicinal Products, Next Article